Detalhe da pesquisa
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38507751
2.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 387(3): 217-226, 2022 07 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35857659
3.
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(4): 499-511, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33676601
4.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Lancet
; 396(10265): 1817-1828, 2020 12 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33278935
5.
Palbociclib and Letrozole in Advanced Breast Cancer.
N Engl J Med
; 375(20): 1925-1936, 2016 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-27959613
6.
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Future Oncol
; 12(11): 1359-67, 2016 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-27020170
7.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Lancet Oncol
; 15(11): 1224-35, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25240821
8.
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Lancet Oncol
; 14(13): 1287-94, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24206640
9.
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Lancet Oncol
; 14(10): 933-42, 2013 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23932548
10.
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
J Clin Oncol
; 42(9): 994-1000, 2024 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38252901
11.
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
J Pathol Clin Res
; 10(3): e12371, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38627977
12.
Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355.
J Natl Cancer Inst
; 2023 Dec 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38070159
13.
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Eur J Cancer
; 195: 113393, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37976633
14.
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.
BioDrugs
; 36(1): 55-69, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-35133617
15.
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Leuk Lymphoma
; 60(14): 3375-3385, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31272251
16.
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Eur J Cancer
; 94: 87-94, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29547835
17.
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
Clin Genitourin Cancer
; 15(1): 72-76, 2017 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27498023
18.
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
J Clin Oncol
; 33(2): 141-8, 2015 Jan 10.
Artigo
Inglês
| MEDLINE | ID: mdl-25185099
19.
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
J Clin Oncol
; 31(14): 1719-25, 2013 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-23569311
20.
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
J Clin Oncol
; 31(30): 3791-9, 2013 Oct 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24019545